Yesterday, President Trump once again choose big drug companies over everyday Americans. His plan broke his promise to do the one thing that would lower prices for tens of millions, allow Medicare to negotiate for a fair price, and its clear winners were the nation’s largest pharmaceutical companies, which saw their stock prices surge after his remarks. Here’s how it was covered, by the headlines:
Wall Street Journal: Trump’s Plan to Cut Drug Prices Leaves Industry Relieved
Bloomberg: Trump’s ‘Sweeping’ Drug-Price Plan Comes Up Short
Reuters: RPT-Trump plan for drug prices seen largely sparing industry
Huffington Post: Trump’s Plan On Prescription Drug Prices Looks Nothing Like What He Promised
Associated Press: President Trump’s Plan to Lower Drug Prices Spares Pharma Industry
Yahoo Finance: Trump lets drug companies off the hook
The Atlantic: Big Pharma Gets a Big Win From Trump
Washington Examiner: Big Pharma largely unscathed by Trump’s drug-price crackdown
Bio Pharma Dive: Pharma breathes easy as Trump’s drug pricing plan fizzles
Chicago Tribune: Trump’s plan to reduce drug prices doesn’t include campaign pledge to allow Medicare to negotiate prices
Endpoints News: Trump’s ‘sweeping action’ to lower drug prices mocked by analysts as relieved investors trigger rally in Big Pharma stocks
Vice: Trump Officially Backed Out of His Own Plan to Make Drugs Cheaper
Kaiser Health News: Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
Investor’s Business Daily: Biopharma Stocks Fly As Trump Speech Seen As ‘More Bark Than Bite’
San Francisco Chronicle: Editorial: Trump’s new drug price strategy won’t change the status quo
New York Daily News: Our opinion: Trump’s bitter pill: His prescription drug plan is weak in one of the most important areas